Phosphatidylserine in Diabetes Research
Molecular Pharmaceutics · 02.01.2023 · 20 (1) · 82-89
DOI: 10.1021/acs.molpharmaceut.2c00707 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, online erschienen am 08.12.2022. Verfasst von Dandan Xiao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Translational Medicine, The Affiliated Hospital, College of Medicine, Qingdao University, Qingdao 266071, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin Resistance. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 66 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Phospholipids are lipids that constitute the basic structure of cell membranes. In-depth research has shown that in addition to supporting cell structures, phospholipids participate in multiple cellular processes, including promoting cell signal transduction, guiding protein translocation, activating enzymatic activity, and eliminating dysfunctional/redundant organelles/cells. Diabetes is a chronic metabolic disease with a complicated etiology and pathology. Studies have shown that the level of certain phospholipids, for example, the ratio of phosphatidylcholine (PC) to phosphatidylethanolamine (PE) in liver tissue, is negatively associated with insulin sensitivity. In addition, PS is a phospholipid exhibiting extensive cellular functions in diabetes. For this review, we analyzed many PS studies focusing on diabetes and insulin sensitivity in recent years and found that PS participates in controlling insulin secretion, regulating insulin signaling transduction, and participating in the progression of diabetic complications by mediating coagulation disorders in the microvasculature or targeting mitochondria. Moreover, PS supplements in food and PS-containing liposomes have been shown to protect against type 1 and type 2 diabetes (T1D and T2D, respectively) in animal studies. Therefore, by summarizing the regulatory roles played by PS in diabetes and the potential of successfully using PS or PS-containing liposomes for diabetic therapy, we hope to provide new ideas for further research into the mechanisms of diabetes and for drug development for treating diabetes and its complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Translational Medicine, The Affiliated Hospital, College of Medicine, Qingdao University, Qingdao 266071, China.
- School of Basic Medical Sciences, College of Medicine, Qingdao University, Qingdao 266071, China.
ORCID-Profile: Wenguang Chang
Zitieren
APA
Xiao, D., & Chang, W. (2023). Phosphatidylserine in Diabetes Research. Molecular Pharmaceutics, 20(1), 82-89. https://doi.org/10.1021/acs.molpharmaceut.2c00707
Vancouver
Xiao D, Chang W. Phosphatidylserine in Diabetes Research. Molecular Pharmaceutics. 2023;20(1):82-89. doi:10.1021/acs.molpharmaceut.2c00707
BibTeX
@article{Xiao2023,
author = {Xiao, Dandan and Chang, Wenguang},
title = {Phosphatidylserine in Diabetes Research},
journal = {Molecular Pharmaceutics},
year = {2023},
volume = {20},
number = {1},
pages = {82--89},
doi = {10.1021/acs.molpharmaceut.2c00707}
}
EUVIMED